Onyx Therapeutics-backed autoimmune drug developer Kezar Life Sciences has closed its initial public offering at $86.3m.

The transplant-based medicine developer, backed by Alphabet, Partners Healthcare and Access Industries, floated in the middle of its range.

The Nan Fung-backed neurologic disorder therapy developer floated at the top of its range, increasing the share volume at the same time.

EMS-backed gene therapy developer AvroBio has secured $99.7m in an initial public offering that could potentially rise to $115m.

Rocket Internet remains the largest investor in the home products marketplace, which has floated in a $174m initial public offering.

Kadmon-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.

United, Mitsui, Itochu and GMO-backed e-commerce platform Mercari has priced its initial public offering at the top of its range and will raise up to $1.19bn in Tokyo this month.

M17 Entertainment, backed by MCN, Yahoo Japan and LeSports, was expected to float on the New York Stock Exchange yesterday but still has not begun trading.

Scholar Rock, a spinal muscular atrophy therapy developer backed by Kraft Group, floated in the middle of its range.